A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Completed · Phase 3 · NCT05260021
Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
At a glance
- Research payments reported, 2025
- $243,173
- U.S. investigators named
- 12
- Sites paid
- 13
- Planned or actual enrollment
- 99
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide Dose 1 (drug), Tirzepatide Dose 2 (drug), Placebo (drug)
- Dates
- Started 2022-04-13; completion 2025-01-28
- Results posted
- Yes
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
From ClinicalTrials.gov, last updated 2025-09-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $243,173 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lily C. Chao, MD Pediatric Endocrinology · Los Angeles, CA
- Karen O. Klein, M.D. Pediatric Endocrinology · San Diego, CA
- Gnanagurdasan Prakasam, MD Pediatric Endocrinology · Sacramento, CA
- Jay H. Shubrook, DO Family Medicine · Vallejo, CA
- Philip Zeitler, MD Pediatric Endocrinology · Aurora, CO
- Chijioke Ikomi, M.D Pediatrics · Wilmington, DE
- Tamara S. Hannon, M.D. Pediatric Endocrinology · Indianapolis, IN
- David E. Schultz II, M.D. Family Medicine · Evansville, IN
- Jennifer E. Sprague, MD Pediatric Endocrinology · Saint Louis, MO
- David W. Hansen, MD Pediatric Endocrinology · Syracuse, NY
- Steven M. Willi, M.D. Pediatric Endocrinology · Philadelphia, PA
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Nemours Children's Hospital, Delaware, DE $63,891
- Regents of the University of California $51,359
- Research Foundation of State Univ of Ny $35,556
- Indiana University $20,777
- Children's Hosp of Los Angeles, CA $17,526
- Cleveland Clinic, OH $13,500
- Washington University $10,104
- Touro University California $9,282
- Children's Hospital Colorado, CO $7,987
- Consano Clinical Research LLC $4,300
- Qualmedica Research LLC $4,086
- Children's Hospital of Philadelphia, PA $3,063
- Sutter Medical Center, Sacramento, CA $1,743
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.